Tags

Type your tag names separated by a space and hit enter

Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans.
Eur J Endocrinol. 2012 May; 166(5):911-6.EJ

Abstract

OBJECTIVE

To clarify the metabolic effects of an overnight i.v. infusion of unacylated ghrelin (UAG) in humans. UAG exerts relevant metabolic actions, likely mediated by a still unknown ghrelin receptor subtype, including effects on β-cell viability and function, insulin secretion and sensitivity, and glucose and lipid metabolism.

DESIGN

We studied the effects of a 16-h infusion (from 2100 to 1300 h) of UAG (1.0 μg/kg per h) or saline in eight normal subjects (age (mean±s.e.m.), 29.6±2.4 years; body mass index (BMI), 22.4±1.7 kg/m(2)), who were served, at 2100 and 0800 h respectively, with isocaloric balanced dinner and breakfast. Glucose, insulin, and free fatty acid (FFA) levels were measured every 20 min.

RESULTS

In comparison with saline, UAG induced significant (P<0.05) changes in glucose, insulin, and FFA profiles. UAG infusion decreased glucose area under the curve (AUC) values by 10% (UAG(0 - 960 min): 79.0±1.7×10(3) mg/dl per min vs saline(0- 960 min): 87.5±3.8×10(3) mg/dl per min) and the AUC at night by 14% (UAG(180)(-)(660 min): 28.4±0.5×10(3) mg/dl per min vs saline(180 - 660 min): 33.2±1.1×10(3) mg/dl per min). The overall insulin AUC was not significantly modified by UAG infusion; however, insulin AUC observed after meals was significantly increased under the exposure to UAG with respect to saline at either dinner or breakfast. The FFA AUC values were decreased by 52% under the exposure to UAG in comparison with saline (UAG(0 - 960 min): 0.3±0.02×10(3) mEq/l per min vs saline(0 - 960 min): 0.6±0.05×10(3) mEq/l per min).

CONCLUSIONS

Exposure to the i.v. administration of UAG improves glucose metabolism and inhibits lipolysis in healthy volunteers. Thus, in contrast to the diabetogenic action of AG, UAG displays hypoglycemic properties.

Authors+Show Affiliations

Division of Endocrinology, Diabetology and Metabolism, Department of Internal Medicine, Molinette Hospital, University of Turin, Corso Dogliotti 14, 10126 Turin, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22379116

Citation

Benso, A, et al. "Metabolic Effects of Overnight Continuous Infusion of Unacylated Ghrelin in Humans." European Journal of Endocrinology, vol. 166, no. 5, 2012, pp. 911-6.
Benso A, St-Pierre DH, Prodam F, et al. Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans. Eur J Endocrinol. 2012;166(5):911-6.
Benso, A., St-Pierre, D. H., Prodam, F., Gramaglia, E., Granata, R., van der Lely, A. J., Ghigo, E., & Broglio, F. (2012). Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans. European Journal of Endocrinology, 166(5), 911-6. https://doi.org/10.1530/EJE-11-0982
Benso A, et al. Metabolic Effects of Overnight Continuous Infusion of Unacylated Ghrelin in Humans. Eur J Endocrinol. 2012;166(5):911-6. PubMed PMID: 22379116.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans. AU - Benso,A, AU - St-Pierre,D H, AU - Prodam,F, AU - Gramaglia,E, AU - Granata,R, AU - van der Lely,A J, AU - Ghigo,E, AU - Broglio,F, Y1 - 2012/02/29/ PY - 2012/3/2/entrez PY - 2012/3/2/pubmed PY - 2012/6/26/medline SP - 911 EP - 6 JF - European journal of endocrinology JO - Eur J Endocrinol VL - 166 IS - 5 N2 - OBJECTIVE: To clarify the metabolic effects of an overnight i.v. infusion of unacylated ghrelin (UAG) in humans. UAG exerts relevant metabolic actions, likely mediated by a still unknown ghrelin receptor subtype, including effects on β-cell viability and function, insulin secretion and sensitivity, and glucose and lipid metabolism. DESIGN: We studied the effects of a 16-h infusion (from 2100 to 1300 h) of UAG (1.0 μg/kg per h) or saline in eight normal subjects (age (mean±s.e.m.), 29.6±2.4 years; body mass index (BMI), 22.4±1.7 kg/m(2)), who were served, at 2100 and 0800 h respectively, with isocaloric balanced dinner and breakfast. Glucose, insulin, and free fatty acid (FFA) levels were measured every 20 min. RESULTS: In comparison with saline, UAG induced significant (P<0.05) changes in glucose, insulin, and FFA profiles. UAG infusion decreased glucose area under the curve (AUC) values by 10% (UAG(0 - 960 min): 79.0±1.7×10(3) mg/dl per min vs saline(0- 960 min): 87.5±3.8×10(3) mg/dl per min) and the AUC at night by 14% (UAG(180)(-)(660 min): 28.4±0.5×10(3) mg/dl per min vs saline(180 - 660 min): 33.2±1.1×10(3) mg/dl per min). The overall insulin AUC was not significantly modified by UAG infusion; however, insulin AUC observed after meals was significantly increased under the exposure to UAG with respect to saline at either dinner or breakfast. The FFA AUC values were decreased by 52% under the exposure to UAG in comparison with saline (UAG(0 - 960 min): 0.3±0.02×10(3) mEq/l per min vs saline(0 - 960 min): 0.6±0.05×10(3) mEq/l per min). CONCLUSIONS: Exposure to the i.v. administration of UAG improves glucose metabolism and inhibits lipolysis in healthy volunteers. Thus, in contrast to the diabetogenic action of AG, UAG displays hypoglycemic properties. SN - 1479-683X UR - https://www.unboundmedicine.com/medline/citation/22379116/Metabolic_effects_of_overnight_continuous_infusion_of_unacylated_ghrelin_in_humans_ L2 - https://eje.bioscientifica.com/doi/10.1530/EJE-11-0982 DB - PRIME DP - Unbound Medicine ER -